Sanstar Limited

Sanstar Limited

95.52
INR
+3.66
(+3.98%)
2.32EPS
52.41P/E
24.33BMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
17
27.68
66.12
59.2
55.46
42.38
43.25
Basic EPS, GAAP
0.76
0.87
2.29
3.66
2.58
1.89
2.32
Free Cash Flow per Basic Share
1.17
1.53
-4.43
-0.64
-3.16
-3.09
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.8
4.68
10.27
13.92
36.17
38.08
- -
Tangible Book Value per Share
3.8
4.68
10.27
13.92
36.17
38.08
- -
Basic Weighted Avg Shares
182
182
182
182
170
182
190
Sales/Revenue/Turnover
3,098
5,044
12,051
10,788
9,416
7,723
8,211
Operating Margin (%)
9.08
6.09
5.03
7.98
4.75
3.46
5.05
Depreciation Expense
89
90
119
121
115
96
125
Net Income, GAAP
139
159
418
668
438
345
440
Effective Tax Rate (%)
15.11
27.58
24.52
25.59
20.41
10.38
14.99
Profit Margin (%)
4.5
3.16
3.47
6.19
4.65
4.46
5.36
Working Capital
185
172
482
924
3,987
2,906
- -
LT Debt
795
575
343
309
147
100
- -
Total Equity
693
852
1,871
2,538
6,591
6,939
- -
Return on Invested Capital (%)
- -
13.03
19.6
19.57
6.59
3.29
- -
Return on Capital (%)
- -
13.03
20.61
21.71
9.27
5.02
- -
Return on Common Equity (%)
- -
20.61
30.7
30.29
9.6
5.09
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
99
- -
LT Borrowings
- -
100
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
182
182
200
Market Capitalization
17,618
13,810
24,327

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
3,553
- -
Cash, Cash Equivalents & STI
- -
674
- -
Accounts Receivable, Net
- -
948
- -
Inventories
- -
421
- -
Total Current Liabilities
- -
646
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
99
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
68.65%
5.28%
Free Cash Flow
- -
-15.55%
5.02%
Net Income, GAAP
- -
36.17%
-21.35%
Sales/Revenue/Turnover
- -
32.11%
-17.98%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
3,027
2,056
2,214
2,269
9,416
2026
1,697
1,964
2,018
2,168
7,723
2027
2,062
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.91
0.43
0.78
0.33
2.58
2026
-0.02
0.03
0.75
1.12
1.89
2027
0.5
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Gouthamchand Sohanlal Chowdhary
Full Time Employees
203
Sector
Consumer non-durables
Industry
Food: major diversified
Address
Sanstar House Ahmedabad GU India 380007
IPO Date
Jul 26, 2024
Website
sanstar.in
Business
Sanstar Ltd Sanstar Limited (SANSTAR.NS) manufactures plant-based specialty products and ingredient solutions derived from maize for food, animal nutrition, pharmaceutical, paper, industrial, and cosmetics applications; core products include native maize starch, liquid glucose, maltodextrin powder, dextrose monohydrate, high maltose corn syrup, modified starches, sorbitol, adhesives, and co-products such as corn gluten meal, corn gluten feed, corn germs, corn fiber, corn steep liquor, and maize gluten meal. The company, originally incorporated as Continental Papers Limited in 1982 and renamed Sanstar Limited in 2012, maintains headquarters in Ahmedabad, India, with manufacturing facilities in Dhule, Maharashtra, and Kutch, Gujarat, offering a total installed capacity of 1,100 metric tons per day across 10.68 million square feet. Sanstar operates as India's third-largest producer of maize-based specialty products, exporting to 49 countries in Southeast Asia, Latin America, Australia, the US, Canada, Africa, the Middle East, Europe, and Oceania while serving 22 states domestically. Recent developments encompass a 2024 initial public offering raising approximately INR 425-500 crore to fund capacity expansion at the Dhule facility by 1,000 tons per day for maize starch, liquid glucose, dextrose monohydrate, and dextrose anhydrous, slated for commercial commencement in fiscal 2026; a merger of erstwhile Sanstar Biopolymers Limited approved by NCLT Ahmedabad in November 2023 transferring assets and liabilities; USFDA registration for the Kutch facility in August 2023 valid through December 2024; and establishment of a research and development center.